Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMV-specific cytotoxic T lymphocytes (Milton S. Hershey Medical Center)
- Development stage
- Unknown
- Lead developer
- Milton S Hershey Medical Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an investigational allogeneic cell therapy consisting of cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTLs) developed by the Milton S. Hershey Medical Center. The therapy is designed to treat refractory glioblastoma multiforme (GBM) by targeting CMV antigens, specifically the pp65 and IE1 proteins, which are frequently expressed in glioblastoma tumor cells but not in healthy brain tissue. The product is composed of donor-derived T cells that are expanded in vitro using CMV peptides and cytokines. This adoptive cellular therapy approach aims to leverage the immune system's existing recognition of CMV to generate a targeted anti-tumor response against GBM cells. It has been evaluated in Phase I-II clinical trials where patients receive lymphodepleting chemotherapy (fludarabine and cyclophosphamide) followed by the CTL infusion.
- Other names
- Allogeneic CMV-specific CTLsCMV-specific CTLCMV-CTLCMV Specific Cytotoxic T Lymphocytes
02
Targets
Cytomegalovirus pp65 peptide-MHC class I complexes
Beyond the preview
Go deeper on CMV-specific cytotoxic T lymphocytes (Milton S. Hershey Medical Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMV-specific cytotoxic T lymphocytes (Milton S. Hershey Medical Center).